STUDY ON NEW TRENDS IN DRUG DELIVERY SYSTEMS
Main Article Content
Keywords
Drug delivery systems, nanocarriers, transdermal patches, microneedle technology, controlled-release formulations
Abstract
Background: Drug delivery science has advanced far beyond conventional tablets and injections, introducing innovative technologies that enhance therapeutic precision, patient comfort, and safety. Objective: To evaluate the awareness, perception, and adoption of emerging drug delivery technologies amongparticipants, including healthcare professionals, pharmacists, and patients.
Methodology: This descriptive cross-sectional study was conducted at Navodaya Medical College Raichur, India. Data were collected using a pretested structured questionnaire assessing knowledge, attitudes, and usage patterns of advanced delivery systems such as nanocarriers, transdermal patches, microneedles, and implantable devices.
Results: Among 255 participants, 55.7% were female and 49.8% held a university-level education. Awareness was highest for transdermal (82.0%) and inhalation systems (87.5%), while only 46.3% were aware of implantable or controlled-release systems. Most respondents (83.1%) agreed that new drug delivery technologies improve treatment precision, and 77.6% believed they reduce side effects. However, 65.5% perceived them as expensive, and only 38.8% felt adequately trained to use them. Adoption was higher for transdermal and inhalation systems, while microneedle and implantable devices showed limited usage.
Conclusion: It is concluded that awareness and acceptance of advanced drug delivery systems are increasing, but their clinical application remains restricted by cost, limited training, and insufficient availability.
References
2. Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8
3. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–87.
4. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC, Tamarkin L, Desai N. Nanomedicines: addressing the scientific and regulatory gap. Ann NY Acad Sci. 2014;1313:35–56.
5. Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev. 2016;2017:9.
6. Sainz V, Conniot J, Matos AI, Peres C, Zupanǒiǒ E, Moura L, Silva LC, Florindo HF, Gaspar RS. Regulatory aspects on nanomedicines. BiochemBiophys Res Commun. 2015;468:504–10.
7. Cheng C, Peng S, Li Z, Zou L, Liu W, Liu C. Improved bioavailability of curcumin in liposomes prepared using a pH-driven, organic solvent-free, easily scalable process. RSC Adv. 2017;7:25978–86.
8. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488. PMID: 37416680; PMCID: PMC10320272.
9. Rayaprolu BM, Strawser JJ, Anyarambhatla G. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm. 2018;44:1565-71. doi:10.1080/03639045.2018.1483392.
10. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5:951-67. doi:10.1038/s41551-021-00698-w.
11. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411. doi:10.3389/fphar.2021.618411.
12. Sahoo D, Bandaru R, Samal SK, Naik R, Kumar P, Kesharwani P, et al. Oral drug delivery of nanomedicine. In: Kesharwani P, Taurin S, editors. Academic Press; 2021. p.181-207.
13. Morales JO, Vuddanda PR, Velaga S. Controlled drug delivery via the buccal and sublingual routes. Fundam Drug Deliv. 2021:433-48.
14. Hussein NR, Omer HK, Elhissi AMA, Ahmed W. Advances in nasal drug delivery systems. In: Ahmed W, Phoenix DA, Jackson MJ, Charalambous SE, editors. Academic Press; 2020. p.279-311.
15. Chauhan A, Fitzhenry L, Serro AP. Recent advances in ophthalmic drug delivery. Pharmaceutics. 2022;14:2075. doi:10.3390/pharmaceutics14102075.
16. Thirunavukkarasu A, Nithya R, Jeyanthi J. Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: a review. Diabetes Res Clin Pract. 2022;109996. doi:10.1016/j.diabres.2022.109996.
17. Sharma P, Gajula K, Dingari NN, Gupta R, Gopal S, Rai B, et al. Subcutaneous drug delivery: a review of the state-of-the-art modelling and experimental techniques. J Biomech Eng. 2022; doi:10.1115/1.4055758.
18. Misbah Ul Haq M, Razzak M, Uddin MA, Ahmed N, Shahidulla D. Rectal drug delivery system: an overview. Clin PharmacolBiopharm. 2021;10.
19. Mahant S, Sharma AK, Gandhi H, Wadhwa R, Dua K, Kapoor DN. Emerging trends and potential prospects in vaginal drug delivery. Curr Drug Deliv. 2022; doi:10.2174/1567201819666220413131243.
20. Cho M, Joo M, Kim K, Wook Y, Lee S, Mi Y, Ho I. Immunotherapeutic effects of recombinant Bacillus … on bladder cancer cells. BiochemBiophys Res Commun. 2018; doi:10.1016/j.bbrc.2018.12.097.
21. Palugan L, Cerea M, Cirilli M, Moutaharrik S, Maroni A, Zema L, et al. Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. Int J Pharm X. 2021;3:100100. doi:10.1016/j.ijpx.2021.100100.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Neeta T Gavimath
Associate Professor, Department of Pharmacology, Raichur, India
Pavan Kumar K
Professor Department of Psychiatry, Raichur, India